Rajesh Kumar
Stock Analyst at HSBC
(2.50)
# 2,125
Out of 5,182 analysts
33
Total ratings
42.86%
Success rate
5.71%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,070 → $850 | $868.27 | -2.10% | 4 | Mar 17, 2026 | |
| PFE Pfizer | Maintains: Buy | $29 → $32 | $26.79 | +19.45% | 2 | Mar 17, 2026 | |
| BIIB Biogen | Maintains: Reduce | $143 → $150 | $180.67 | -16.98% | 2 | Mar 17, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $60 | $57.78 | +3.84% | 3 | Mar 17, 2026 | |
| ABBV AbbVie | Upgrades: Buy | $225 → $265 | $197.38 | +34.26% | 5 | Dec 10, 2025 | |
| NVO Novo Nordisk | Downgrades: Hold | n/a | $41.20 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $163.84 | +43.43% | 2 | Oct 9, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $28.15 | +49.20% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $468.04 | +43.15% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $180.62 | +55.02% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $460 | $354.69 | +29.69% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $31.26 | -58.41% | 1 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $48.70 | +99.18% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $102.06 | +21.50% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $110.23 | +11.58% | 1 | Jul 14, 2023 |
Eli Lilly and Company
Mar 17, 2026
Downgrades: Reduce
Price Target: $1,070 → $850
Current: $868.27
Upside: -2.10%
Pfizer
Mar 17, 2026
Maintains: Buy
Price Target: $29 → $32
Current: $26.79
Upside: +19.45%
Biogen
Mar 17, 2026
Maintains: Reduce
Price Target: $143 → $150
Current: $180.67
Upside: -16.98%
Bristol-Myers Squibb Company
Mar 17, 2026
Maintains: Hold
Price Target: $53 → $60
Current: $57.78
Upside: +3.84%
AbbVie
Dec 10, 2025
Upgrades: Buy
Price Target: $225 → $265
Current: $197.38
Upside: +34.26%
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $41.20
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $163.84
Upside: +43.43%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $28.15
Upside: +49.20%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $468.04
Upside: +43.15%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $180.62
Upside: +55.02%
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $354.69
Upside: +29.69%
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $31.26
Upside: -58.41%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $48.70
Upside: +99.18%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $102.06
Upside: +21.50%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $110.23
Upside: +11.58%